What does the pharmacological future of treating chronic hepatitis C look like?
Development of direct acting antivirals has revolutionized the standard of care for the treatment of hepatitis C virus. New interferon-free regimens provide sustained virologic response rates of >90% in many genotype 1 patients with only 12 weeks of oral therapy. This review will provide a brief overview of current standards of care with a summary of the evidence supporting the recommended combinations of direct acting antivirals. We will discuss the direction of future therapies, with strategies for shorter durations of therapy and new all-oral combinations in the pipeline.
a 1 Department of Pharmacy, University of Maryland Medical Center, 29 S. Greene St, Room 400, Baltimore, MD 21201, USA.
Emily L
EL
Heil
Lauren M
LM
Hynicka
Shyam
S
Kottilil
Lydia
L
Tang
D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects* / Q000235:genetics; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000821:virology; D006801:Humans; D013997:Time Factors
D000998:Antiviral Agents
direct acting antivirals; hepatitis C virus; interferon-free regimens; ledipasvir; sofosbuvir